Answers are grounded in this paper and cite their sources.
Clinically evident interstitial lung disease (ILD) occurs in 10% of patients with rheumatoid arthritis (RA) and is associated with considerable morbidity and mortality [1. RA-associated ILD (RA-ILD) has a poor prognosis with a highly variable and unpredictable clinical course [2]. Although several prognostic factors, including older age, male sex, reduced lung function, and a usual interstitial pneumonia (UIP) pattern or extensive disease on high-resolution computed tomography (HRCT) have been proposed [3], their predictive capacity may be limited by insufficient respiratory effort or interobserver variability. Circulating free mitochondrial DNA (mtDNA) is released from dying cells into the circulatory system in response to injury [4] and is associated with the pathogenesis of various conditions, including ILD [5–8]. Circulating mitochondrial DNA might be a useful prognostic biomarker in patients with rheumatoid arthritis-associated interstitial lung disease <https://bit.ly/3HFqhQM> We thank Hak-Su Kim (Veterans Medical Research Institute, Veterans Health Service Medical Center, Seoul, Republic of Korea) for the valuable comments regarding the measurement of plasma mtDNA levels, Seokchan Hong (Department of Rheumatology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea) for the confirmation of RA-ILD cases, and Jooae Choe (Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea) for radiological analysis.
No takes yet. Share an insight, caveat, or question.
Yoon et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: